期刊
EXPERT OPINION ON DRUG SAFETY
卷 20, 期 6, 页码 623-625出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2021.1907342
关键词
CGRP(r) monoclonal antibodies; combination therapy; ditans; drug-drug interactions; gepants; migraine; onabotulinumtoxin-A